Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair [Yahoo! Finance]
Aerovate Therapeutics, Inc. (AVTE)
Company Research
Source: Yahoo! Finance
on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. “We are pleased to have Habib take on the role of Chair of the Board,” said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. “With the Phase 2b data readout from our global IMPAHCT trial of AV-101 in PAH coming in June and our Phase 3 trial already well underway, his leadership and deep expertise in drug development and commercialization will be invaluable as we begin building towards the future. I would also like to thank Mark for his significant contributions and commitment to Aerovate, and I look forward to continuing to work together.” “I am honored to assume the role of Board Chair for Aerovate during this exciting time for the company,” said Mr. Dable. “I look forward to continuing to work w
Show less
Read more
Impact Snapshot
Event Time:
AVTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVTE alerts
High impacting Aerovate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AVTE
News
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.MarketBeat
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $35.00 price target on the stock.MarketBeat
- Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceGlobeNewswire
- Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsGlobeNewswire
AVTE
Earnings
- 11/13/23 - Miss
AVTE
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- AVTE's page on the SEC website